Navigation Links
Blood sugar improves with first gastrointestinal microbiome modulator, NM504
Date:6/23/2014

CHICAGO, IL In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerancethe body's response to consuming carbohydrates after four weeks of treatment and without a change in diet. These results, from a pilot study, will be presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

The not-yet-named therapeutic, NM504, is the first in a new class of therapies known as GI microbiome modulators. The GI microbiomethe mix of microbial and associated physical and chemical factors in the digestive systemmay play a critical part in regulating the body's metabolism, some researchers believe. There is recent scientific evidence that microbial imbalance, or dysbiosis, in the gut contributes to the development of Type 2 diabetes.

"We believe that modern Western diets contribute to development of Type 2 diabetes, in part because they change the habitat of the microorganisms that reside in the gut. This shifts the microbial populations that live there in ways that affect metabolic health," said Mark Heiman, PhD, the study's principal investigator. Heiman is chief scientific officer for MicroBiome Therapeutics, the Colorado-based biotechnology company that is developing NM504 and sponsored the study.

NM504 is designed to shift the GI bacteria and other microorganismscalled microbiotaand their environment in specific ways to achieve improved health outcomes, according to Heiman. He said the drug contains concentrated bioactive food ingredients: inulin, a fiber; beta-glucan and polyphenolic antioxidant compounds.

Heiman and colleagues conducted a study in 28 adults with prediabetes, a frequent precursor to Type 2 diabetes. Fourteen subjects were randomly assigned to receive NM504 twice a day, and the other 14 were assigned to receive placebo, or "dummy" material. Neither the subjects nor the investigators were aware of the drug assignments. Before any treatment and again at four weeks of treatment, all subjects had an oral glucose challenge. In this test, they drank a concentrated glucose (sugary) drink and then had their blood sugar levels tested at various times and compared with pretest levels.

Blood sugar levels at 120 and 180 minutes after the glucose challenge were significantly lower in subjects who took NM504 than those who received the placebo, Heiman reported. Also during this test, NM504 increased insulin sensitivity, the body's ability to successfully clear glucose from the bloodstream.

Compared with placebo, NM504 treatment also decreased the desire to eat, which Heiman said Microbiome Therapeutics' researchers had hoped the therapeutic would do. He said the subjects tolerated NM504 well, with only a mild increase in flatulence, or gas.

"This work indicates a new therapeutic targetthe GI microbiomethat has the potential to revolutionize the treatment of metabolic diseases such as Type 2 diabetes," Heiman commented.

MicroBiome Therapeutics reports that the company plans to develop NM504 and/or a closely related therapeutic as a prescription medicine to treat prediabetes and diabetes.


'/>"/>
Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: